Search Prime Grants

R01AI172086

Project Grant

Overview

Grant Description
Investigate the mechanisms underlying microRNA-146a activity in regulation of foreign body response to biomaterials - project summary.

Implantation of biomaterials and devices often leads to the development of a foreign body response (FBR), a chronic inflammatory condition that can ultimately lead to implant failure, which may cause harm to or death of the patient. The molecular mechanisms underlying the FBR remain poorly understood.

Improved understanding of the molecular mechanisms underlying the generation of FBR is the most important step for the development of novel and effective therapeutic strategies that eliminate or reduce the FBR.

Macrophages are central to development and progression of the FBR. They participate in the expression of inflammatory proteins, formation of destructive foreign body giant cells (FBGCs), remodeling of the extracellular matrix, and encapsulation of the implant.

Emerging data support a critical role for a mechanical signal, e.g., matrix stiffness, in macrophage activation.

MicroRNAs (miRs) are endogenous, small, non-coding RNAs that have emerged as powerful regulators of gene expression in numerous cellular processes including macrophage activation, cell fusion, inflammation, and fibrosis.

The function of specific miRs in regulation of FBR to biomaterials is uncertain; specifically, it remains an open question whether matrix stiffness regulates miR expression to drive FBR.

These gaps pose a significant barrier to progress in the FBR field.

In recent, exciting preliminary data, we obtained evidence that miR-146a may be a negative regulator of FBR to biomaterials. Specifically, we found that:

1) miR-146a expression levels decreased in the implant-adhered tissues in a subcutaneous (S.C) implantation model, which correlated with increased macrophage accumulation, FBGC formation, and collagen accumulation;

2) miR-146a deletion in mice exacerbated FBR processes in a S.C implantation model;

3) the severity of the in vivo macrophage accumulation at the tissue-implant interface was dependent on the stiffness of the implant;

4) genetic ablation of miR-146a augmented macrophage adhesion and spreading on stiff matrix, FBGC formation, and inflammation in macrophages; and

5) genetic ablation of TRPV4, an ion channel in the transient receptor potential vanilloid family, inhibited development of implant-adhered tissue stiffness under FBR as determined by atomic force microscopy.

Further preliminary data suggested an association between matrix stiffness, miR-146a activity, and TRPV4, under FBR conditions.

The objective of this proposal is to define the role of miR-146a in the FBR, and to elucidate the underlying molecular mechanisms.

Based on our preliminary data, our central hypothesis is that miR-146a modulates the FBR to biomaterials by regulating macrophage activation and fibrogenesis in a manner dependent on implant-induced change in tissue stiffness.

We will test our hypothesis through molecular gain- or loss-of-function studies.

We expect that the results of this study may provide invaluable information and insight regarding the molecular mechanisms mediating the FBR to biomaterials, which may lead to the development of a novel and effective microRNA-based therapeutic strategy for the amelioration of the poorly understood FBR to biomaterials.
Funding Goals
NOT APPLICABLE
Place of Performance
College Park, Maryland 20742 United States
Geographic Scope
Single Zip Code
Analysis Notes
Amendment Since initial award the total obligations have increased 385% from $736,942 to $3,572,444.
College Park University Of Maryland was awarded MicroRNA-146a Regulation of Foreign Body Response to Biomaterials Project Grant R01AI172086 worth $3,572,444 from the National Institute of Allergy and Infectious Diseases in September 2017 with work to be completed primarily in College Park Maryland United States. The grant has a duration of 9 years 8 months and was awarded through assistance program 93.855 Allergy and Infectious Diseases Research. The Project Grant was awarded through grant opportunity NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed).

Status
(Ongoing)

Last Modified 6/5/26

Period of Performance
9/10/17
Start Date
5/31/27
End Date
90.0% Complete

Funding Split
$3.6M
Federal Obligation
$0.0
Non-Federal Obligation
$3.6M
Total Obligated
100.0% Federal Funding
0.0% Non-Federal Funding

Activity Timeline

Interactive chart of timeline of amendments to R01AI172086

Subgrant Awards

Disclosed subgrants for R01AI172086

Transaction History

Modifications to R01AI172086

Additional Detail

Award ID FAIN
R01AI172086
SAI Number
R01AI172086-1289225558
Award ID URI
SAI UNAVAILABLE
Awardee Classifications
Public/State Controlled Institution Of Higher Education
Awarding Office
75NM00 NIH National Institute of Allergy and Infectious Diseases
Funding Office
75NM00 NIH National Institute of Allergy and Infectious Diseases
Awardee UEI
NPU8ULVAAS23
Awardee CAGE
0UB92
Performance District
MD-04
Senators
Benjamin Cardin
Chris Van Hollen

Budget Funding

Federal Account Budget Subfunction Object Class Total Percentage
National Institute of Allergy and Infectious Diseases, National Institutes of Health, Health and Human Services (075-0885) Health research and training Grants, subsidies, and contributions (41.0) $1,454,743 98%
Modified: 6/5/26